Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Core Viewpoint - Senseonics Holdings, Inc. is actively participating in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, indicating its commitment to engaging with investors and stakeholders in the medical technology sector [1]. Company Overview - Senseonics Holdings, Inc. specializes in the development and manufacturing of long-term implantable continuous glucose monitoring (CGM) systems aimed at improving the lives of individuals with diabetes [3]. - The company's CGM systems, Eversense® 365 and Eversense® E3, feature a small sensor that is fully implanted under the skin and communicates with a smart transmitter worn externally, providing glucose data to a mobile app every 5 minutes [3]. Investor Relations - Investors interested in meeting with Senseonics during the conference are encouraged to contact their BTIG representatives for arrangements [2]. - The investor contact for Senseonics is Jeremy Feffer from LifeSci Advisors, who can be reached via the provided email [4].